Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
hAECs in Severe Refractory Asherman's Syndrome
NCT03223454Phase 1Unknown
- Sponsor
- The 2nd Affiliated Hospital of Chongqing Medical University
- Start
- Oct 2017
- Primary completion
- Sep 2019
- Modality
- Mesenchymal Stem Cells
01
Overview
Phase 1, randomised, single-blind trial of human amniotic epithelial stem cells in Asherman's syndrome (AS) (5 arms), sponsored by The 2nd Affiliated Hospital of Chongqing Medical University. Primary endpoint: Menstrual blood volume at 3 months. Status: unknown.
02
Drugs
human amniotic epithelial stem cells
03
Conditions
Asherman's syndrome (AS)
Beyond the preview
Go deeper on NCT03223454.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03223454.